vedevax BLOCK
PATENT
PCT/ES/070053.P080101073
AGREEMENT
APCH1 Platform
Unlike standard vaccines, in which the immune system finds the vaccine antigen, recognizes it as foreign, and then triggers an immune response, the APCH1 platform allows presenting the antigen directly to the immune cells.
The APCH1 platform is based on the use of a single-chain antibody that recognizes the preserved site of the MHC type II molecule, on the surface of antigen-presenting cells, to which proteins of different pathogens can be fused.
The first subunit recombinant vaccine licensed
against the bovine viral diarrhea virus
Vedevax is the first subunit recombinant vaccine in the world licensed against the Bovine Viral Diarrhea virus (BVDV), a disease that affects many cattle herds. Unlike traditional vaccines, its production is based on the combination of viral E2 glycoprotein with the APCH antibody, which has affinity for the immune system. This mechanism greatly increases its effectiveness.
